PHENYLEPHRINE, (±)-
Chemotherapy Effect
Kansas State UniversitySmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 81/ 100
Competitive context
32 Active assets in the Chemotherapy Effect cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Docetaxel The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 4 | BB |
Idarubicine Fujian Medical University Union Hospital | Phase 4 | BB |
Eloxatin Linhui Peng | Phase 3 | BB |
Calcium folinate pentahydrate Sun Yat-sen University | Phase 3 | BB |
Vinorelbine Zhiyong Yu | Phase 3 | B |
View all 50 →
Same molecule, other indications
PHENYLEPHRINE, (±)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →